Jimmy Hu, MD
Ophthalmology · New York, NYNPI 1962814806
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 81 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Alcon at 42.1% of the total. Reporting peaked in 2024 at $932 and has fallen 59.0% since, to $382 in 2025.
Across 81 payments — averaging $39.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$1K
- Johnson & Johnson Surgical Vision, Inc.$289
- Sun Pharmaceutical Industries Inc.$263
- Rxsight Inc$233
- Bausch & Lomb Americas Inc.$222
- AbbVie$178
- plus $674 from 10 others
Across 2 payments — averaging $22,388 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alcon Research LLC$45K
What the payments were for
- Travel & lodging$120%
- Food & beverage$3,18399%
- Gifts$191%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 25 | $1,355 |
| Johnson & Johnson Surgical Vision, Inc. | 6 | $289 |
| Sun Pharmaceutical Industries Inc. | 9 | $263 |
| Rxsight Inc | 2 | $233 |
| Bausch & Lomb Americas Inc. | 3 | $222 |
| AbbVie(2 entities) | 8 | $178 |
| Oyster Point Pharma, Inc. | 3 | $164 |
| Novartis | 6 | $119 |
| Kala Pharmaceuticals, Inc. | 5 | $110 |
| Biotissue Holdings Inc. | 4 | $92 |
| Dompe US, Inc. | 4 | $76 |
| Tarsus Pharmaceuticals, Inc. | 2 | $33 |
| Harrow Eye, LLC | 1 | $25 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Eyevance Pharmaceuticals LLC | 1 | $18 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Clareon$256
- RXSIGHT CONTACT LENS$233
- RXSIGHT INJECTOR CARTRIDGE$233
- RXSIGHT INJECTOR HANDPIECE$233
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$233
- LIGHT ADJUSTABLE LENS (LAL)$233
- Tecnis IOL$129
- CEQUA$125
- AcrySof IQ VIVITY$125
- TYRVAYA$124
- MIEBO$120
- XIIDRA$120
- ARGOS$110
How this compares
$3,214 in reported general payments places this provider in the 70th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 16 | $19,831 |
| XiidraLifitegrast | 24 | $16,570 |
| Prednisolone Acetate | 269 | $13,472 |
| Cyclosporine | 18 | $9,049 |
| Ketorolac Tromethamine | 216 | $6,252 |
| Ofloxacin | 207 | $2,399 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 139 | $1,365 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 11 | $1,158 |
| Latanoprost | 70 | $260 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis | $178 | $19,83116 claims |
| Bausch & Lomb Americas Inc.Xiidra | $222 | $16,57024 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,587 ophthalmology providers in New York.
Other ophthalmology in New York
- Nathan RadcliffeNew York$2.1M
- Richard SpaideNew York$1.7M
- Joshua YoungNew York$814K
- Joseph PanarelliNew York$541K
- Eric RosenbergNew York$434K
- Michael CooneyNew York$398K
- David GuyerNew York$322K
- Ashley BrissetteNew York$315K
- Jason SlakterNew York$272K
- David ChuNew York$234K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.